Actively Recruiting
Eggs and Age-related Macular Degeneration (EggsAMD) Study.
Led by Kathryn Starr · Updated on 2026-01-07
20
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.
CONDITIONS
Official Title
Eggs and Age-related Macular Degeneration (EggsAMD) Study.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with intermediate dry AMD as noted in their medical record (multiple medium drusen, at least one large druse >125 bcm, and/or non-center involving geographic atrophy) with stable vision (BCVA change <10 letters on EDTRS chart within 6 months)
- 55 years of age and older
- Willing to limit egg consumption for one month before starting the study
- Willing to follow the diet protocol
- Body Mass Index between 22.0 and 39.9 kg/m2
- Access to refrigeration
- Access to reliable transportation
You will not qualify if you...
- Presence of retinal diseases such as central geographic atrophy, hemorrhage, retinal fluid, or other macular pathology besides AMD
- Presence of dense cataracts
- Presence of glaucoma
- Previous retinal laser or surgery affecting retinal integrity
- Any other eye condition requiring long-term therapy or surgery during the study
- Significant corneal or media opacities that prevent proper eye imaging and testing
- Diagnosis of nystagmus interfering with testing
- Egg allergy
- Uncontrolled high cholesterol (over 240 mg/dL in last 12 months) unless under active treatment to reduce it below 240 mg/dL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke Center for Living
Durham, North Carolina, United States, 27705
Actively Recruiting
Research Team
J
Johanna Johnson, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here